GSK responds to 60 Minutes | Related Video
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) issued the following response regarding a 60 Minutes program on January 2 that focused on a manufacturing facility in Puerto Rico which was formerly owned by the company.
First two clinical phase III studies confirm the profile of nalmefene
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) announced the completion of two out of three pivotal studies in the phase III clinical programme for nalmefene in alcohol dependence (ESENSE1 and SENSE). The studies were conducted in Europe and enrolled about 1,300 patients with alcohol dependence.
European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
- Details
- Category: Novartis
Novartis received approval from the European Commission for Tasigna® (nilotinib) as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Ascendis Pharma (Ascendis) announced a global licensing and patent transfer agreement on Ascendis' proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect.
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) has submitted supplemental applications to both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to expand the use of Prevnar 13®* to adults 50 years of age and older for the prevention of pneumococcal disease caused by the 13 serotypes contained in the vaccine.
Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement
- Details
- Category: Novo Nordisk
Emisphere Technologies, Inc. (OTC BB: EMIS) and Novo Nordisk A/S (NYSE: NVO) have entered into an exclusive Development and Licence Agreement to develop and commercialise oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology.
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
More Pharma News ...
- Genzyme Details Market Potential of Alemtuzumab for MS
- EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
- Merck KGaA and sanofi-aventis to Investigate Novel Combinations Against Cancer
- Roche provides update on Avastin following reviews in Europe and the United States
- Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
- Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.
- Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China